SILENCE THERAP. SP.ADR/1 (XRP2) — Strategic Asset Allocation Index
SILENCE THERAP. SP.ADR/1 (XRP2) has a Strategic Asset Allocation Index of 0.3% as of September 2024. Strategic assets (PP&E of €- plus long-term investments of €380.05K) total €380.05K, measured against net assets of €126.48 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See SILENCE THERAP. SP.ADR/1 balance sheet quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
SILENCE THERAP. SP.ADR/1 Strategic Asset Allocation Index (2021–2023)
This chart shows how SILENCE THERAP. SP.ADR/1's Strategic Asset Allocation Index has evolved across 3 annual periods from 2021 to 2023. As of September 2024, the index stands at 0.3%, representing strategic assets of €380.05K against net assets of €126.48 Million EUR. For live market cap and overall valuation, see XRP2 company net worth.
Annual Strategic Asset Allocation Index for SILENCE THERAP. SP.ADR/1 (2021–2023)
The table below presents the year-by-year Strategic Asset Allocation Index for SILENCE THERAP. SP.ADR/1 from 2021 to 2023, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See SILENCE THERAP. SP.ADR/1 shareholders equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2023 | 1.6% | €361.79K | €- | €361.79K | €21.99 Million | ▲ +0.4 pp |
| 2022 | 1.3% | €343.70K | €- | €343.70K | €26.71 Million | ▼ -2.2 pp |
| 2021 | 3.5% | €406.24K | €- | €406.24K | €11.51 Million | — |